Tests of specific and non-specific immunity

Tests of specific immunity
1. The reaction of blasttransformation lymphocytes (RBT). Determined morphological methods in a three-day culture of lymphocytes under the action of pithamagan (PHA)and water-salt extract and glycoproteins fractions derived from tumor tissue of the patient. RBT some patients increased up to 20-24% (norm 8%).
2. Response inhibition of migration of leukocytes (RTM) is investigated capillary method. As antigen used the same water-salt extract and glycoprotein fraction of the tumor.

The tests are non-specific immunity
1. The reaction of spontaneous resetcodepage (ROCK). Based on the ability of T-cells to form rosette with sheep erythrocytes. According to C. F. Semiglazov et al. (1978), almost half of the patients with breast cancer, the number of immune cells is significantly less than a multiyear average (of 7.8 - 8.3%) and correlates with increased levels of cortisol.
2. Reactions of cell delayed-type hypersensitivity (GST), including skin tests with tuberculin in dilution 1 : 100, Candida antigen, antigen of Staphylococcus aureus and so-called contact allergen - dinitrochlorobenzene (DNCB). At diameter of skin papules more than 5 cm, especially when using two or three antigens, there is a clear difference between the cancer patients and the control group of healthy women.
3. Phagocytic activity of lymphocytes (FAL). Is determined in cooperation with the daily culture of Staphylococcus aureus. Activity decrease, with a simultaneous increase of pathogenic skin autoflora there is some patients with breast cancer, mainly in the developed forms of the disease.
Although the assessment of immunological reactivity as measured by those tests are still cannot be considered as the indicator of protective and adaptive forces, as there is no direct correlation between them and the clinical manifestations of a tumor, yet most scholars emphasize the fact oppression immunological reactivity in the third and even more often in stage IV, and a certain recovery of the it - in 6-12 months after the successful completion of therapeutic measures in patients with early forms of the tumor. Apparently, it is possible to consider that immunological depression increases in proportion to the degree distribution process and disappears (or decreases) with a favorable response to treatment (Baral et. al., 1977).
Thus, assessment of the biological properties of the tumor and the body allows you to make rational plan of remedial measures, consistent implementation of which can affect the timing of relapse-free flow and duration of life of the patient.